1. Introduction {#s0005}
===============

Endemic Burkitt Lymphoma (eBL) is the most common pediatric cancer in sub-Saharan Africa ([@bb0165]). Similarity in the geographical distribution of endemic eBL and *Plasmodium falciparum* (*Pf*) malaria ([@bb0085]) and association between high titers of anti-malaria antibodies and eBL risk in case-control studies ([@bb0035], [@bb0140]) have lent support to the hypothesis that malaria is causally-related to risk of eBL. However, concern about reverse causation, confounding([@bb0080]), and limited understanding of malaria antibody responses ([@bb0210]), undermines the inferences that can be made using evidence from ecological and case-control studies. For example, high titer of antibodies against *Pf* malaria whole schizont lysate ([@bb0140], [@bb0035]) and histidine rich protein 2 antigens are associated with high risk of eBL in children ([@bb0010]), whereas high titer of antibodies against *Pf* malaria SERA5 (SE36) ([@bb0010]), a blood-stage vaccine candidate, is associated with decreased risk of eBL.

The Mendelian distribution of polymorphisms related to malaria resistance, such as rs334-A/T in the hemoglobin gene (*HBB*) that causes the sickle cell trait (SCT) ([@bb0095]) can be utilized to investigate the effect of malaria on outcomes ([@bb0200]) such as stunting ([@bb0105]), bacteremia ([@bb0195]), hypertension([@bb0065]), or eBL. In 1966, Williams reported a statistically significant 2-fold lower frequency of SCT in 100 eBL cases compared to 320 hospital-based controls aged 5--15 years in Nigeria ([@bb0225]). Two studies conducted in Uganda in 1970 ([@bb0175]) and Ghana in 1976 ([@bb0150]) were inconclusive, but they were limited by small sample sizes with lower power, and lack of covariate data to control for confounding or population structure ([@bb0180]). Recently, a study in Kenya reported a null association between SCT and eBL risk ([@bb0135]), while a small study in Cameroon reported an inverse association with eBL risk ([@bb0090]). The Kenyan study had a large sample size (306 cases and 537 controls), but it was not population-based, was limited by selection bias of the controls sampled only from two villages, and adjustment only for sex and age ([@bb0135]).

In this study, we investigated the association between malaria and eBL using a Mendelian Randomization study of SCT and other polymorphisms that potentially affect malaria risk using data from the **E**pide**m**iology of **B**urkitt **L**ymphoma in **E**ast African Children and **M**inors (EMBLEM) study in Northern Uganda.

2. Materials and Methods {#s0010}
========================

2.1. Subjects, Design, and Participants {#s0015}
---------------------------------------

We investigated the causal role of malaria infection on eBL risk using Mendelian Randomization ([@bb0200]). Population-based eBL cases aged 0 through 15 years and healthy controls frequency-matched on age, sex, and geographical region were enrolled in EMBLEM from November 11, 2011 to April 15, 2015 ([@bb0130]). eBL cases were clinically stable patients enrolled before starting chemotherapy at St. Mary\'s Hospital, Lacor, in Gulu district and Kuluva Hospital in Arua district from the north-central and northwest regions, respectively. These hospitals were the best equipped to diagnose and treat eBL in northern Uganda. eBL case identification was enhanced using eBL awareness posters, radio programs, and regular outreach to encourage referral of suspected cases to the two hospitals for histological diagnosis and treatment. We restricted case enrollment to the north-central and northwest regions because we wanted a well-defined referent population that could be efficiently targeted for case identification and sampling of population controls. The annual entomological inoculation rate in the study area varies from 397 infectious mosquito bites per year in the northwest region to 1586 infectious bites per year in the north-central region ([@bb0170]). The eBL incidence in these regions is also high (1--7 cases per 100,000 children) ([@bb0160]).

The controls were enrolled as previously described ([@bb0130]). Briefly, 100 villages were randomly selected from a list of all villages in the study area, stratified by geographical surrogates of malaria transmission risk, namely - rural/urban location, and village proximity to surface water (defined as a swamp, river, or lake). About three unrelated controls per case were selected from a random set of children who had lived in the study area for at least four months before enrollment, and frequency-matched on sex, age group (0--2, 3--5, 6--8, 9--11, 12--15 years), and geographical distribution of the historical eBL cases from the study area ([@bb0160]). Structured questionnaires were administered to the eBL cases at the hospital and to the controls at their home to record age, sex, the region of residence, and information about in- and out-patient malaria treatment (0--6 months, 7--12 months, or \> 13 months ago). Peripheral blood samples for research were collected in 10 ml EDTA tubes from cases at the hospital, and from healthy controls at their home. Additional blood samples were collected in 4 ml EDTA tubes for clinical tests and immediately tested for malaria infection, as previously described, ([@bb0130]) and for hemoglobin level (g/dl) using QBC Star Dry Hematology Analyzer (Drucker Diagnostics, Port Matilda, PA). The research blood samples were transported in cold boxes to local EMBLEM field laboratories within two hours from sampling, and centrifuged (Eppendorf Centrifuge, Thermo Scientific, Atlanta, GA) for 15 min at 1300*g* to separate plasma, buffy coat, and red cell fractions. These blood fractions were stored in barcoded cryovials at − 800 °C in local temperature-monitored freezers until shipment in liquid nitrogen to the National Cancer Institute (NCI) Frederick National Cancer Laboratory, Frederick, MD, USA, for long-term storage.

2.2. Ethical Issues {#s0020}
-------------------

The study implementation conformed to the standards indicated by the Declaration of Helsinki. Ethical approval was given by the Uganda Virus Research Institute Research and Ethics Committee, the Uganda National Council for Science and Technology, and the NCI Special Studies Institutional Review Boards. Written informed consent was obtained from the guardians of all participants, and informed assent was obtained from the participants aged ≥ 8 years old.

2.3. Procedures {#s0025}
---------------

Genomic DNA was extracted from previously unthawed buffy coat samples using the Qiagen QIAsymphony automated instrument at the NCI Cancer Genomics Research (CGR) Laboratory, USA. All genotyping was performed blinded at the NCI, USA using the Infinium Omni5Exome-4 v1.3 BeadChip (Illumina, San Diego, CA, USA; 4,641,218 SNPs), TaqMan assays (Supplementary Table 3), or Sanger sequencing (for rs334 in *HBB*, Supplementary Fig. 1). Illumina chip genotypes available on 125 eBL cases and 342 controls were used to prioritize SNPs for evaluation in the current study ([Fig. 1](#f0005){ref-type="fig"}) and to define population structure using principal components analysis (PCA) performed on the genotypes of 700,000 genome-wide SNPs ([@bb0180]). Significant eigenvectors were found to correlate with the region of enrollment (northwest or north-central). Thus, the region of enrollment was used to adjust for ancestry in all analyses in the total data set that also included samples without genome-wide Illumina data.Fig. 1Flow chart showing strategy for selecting index single nucleotide polymorphisms (SNPs) or their proxies for evaluation in the current study.Fig. 1

As shown in [Fig. 1](#f0005){ref-type="fig"}, we selected 73 SNPs in 13 genes (Supplementary Table 1) to test their associations with eBL risk in 125 eBL cases and 342 controls with the Illumina genotypes. These 73 SNPs were selected by identifying a core set of 31 index SNPs (Supplementary Table 2), as instrumental variables for malaria exposure, based on published literature on the polymorphisms associated with protection against severe malaria infection or immune response to malaria. Nineteen of the 31 index SNPs were present on the Illumina chip, and 54 proxy SNPs were selected for being in strong linkage disequilibrium (LD) (r2 \> 0.8 or/and D′ \> 0.8) with the 19 index SNPs. Five SNPs (two index and three proxy SNPs) not in Hardy-Weinberg equilibrium (HWE) in the controls (p \< 0·05) were excluded at this stage. The remaining 68 SNPs (17 index and 51 proxy) were evaluated for association with eBL in the 125 eBL cases and 342 controls (Supplementary Fig. 2 and Supplementary Table 1). Thirteen SNPs (four index and nine proxy SNPs, Supplementary Table 3) in six genes associated with eBL (p \< 0·05) at this stage were prioritized for further analysis. These 13 SNPs were re-genotyped with TaqMan assays or Sanger sequencing for technical validation of the Illumina chip results, with 100% concordance, and genotyped in an additional 77 eBL cases and 282 controls to increase sample size. Three *IFNAR1* SNPs (rs2253413, rs914141, and rs2856973) not in HWE in the total set of controls (p \< 0·05) were excluded, leaving ten SNPs, 202 cases and 624 controls for analysis in the total set.

2.4. Statistical Analysis {#s0030}
-------------------------

HWE for each SNP was evaluated with *χ*^2^ tests in the controls. Odds ratios and 95% confidence intervals (ORs, 95% CIs) for the association of each SNP with risk of eBL, or malaria in controls, were estimated using logistic regression. We used likelihood ratio tests to compute p-values, with p \< 0·05 being considered significant. Statistical tests were two-sided. SNP genotypes were coded using an additive genetic model that counts the number of minor alleles. Genotypes for uncommon alleles were coded by combining the minor homozygotes and heterozygotes in one group. Models were adjusted for possible confounders selected a priori based on their known associations with malaria infection status ([@bb0130]), including age groups (0--2, 3--5, 6--8, 9--11, 12--15 years), sex, malaria transmission risk (rural/urban and proximity to surface water based on village boundary within/more than 500 m), malaria infection status based on thick film microscopy or rapid diagnostic test ([@bb0130]), and lifetime malaria treatment as an inpatient or outpatient. As fever at the time of enrollment was rare (observed in only 2.1% of the controls), malaria test positivity in the controls was considered asymptomatic and incidental. Population structure was adjusted for by including into analysis region of enrollment ([@bb0180]), which was correlated with eigenvectors in the PCA. Missing data was coded as a specific category, but individuals with missing data for the exposure variable of interest were excluded from the model when estimating the association. Analyses were performed using Stata SE 14 (College Park, TX). Because malaria immunity increases with age, with younger children relying more on innate immunity to control infection and older children relying more on adaptive immunity ([@bb0230]), analyses of eBL risk were stratified on age (\< 9 years, 124 eBL cases) versus older children (9--15 years, 78 eBL cases), based on the peak age of malaria prevalence in the controls ([@bb0130]). We evaluated the associations between asymptomatic malaria infection, defined as described above, with the ten SNPs in secondary analyses restricted only to the controls. We estimated that a study of 465 subjects in 1:3 case-control ratio would have 80% power to reject a null hypothesis that SCT is randomly distributed in the cases and controls at an α = 0.05 and a prevalence of SCT of 20% in the general population in northern Uganda ([@bb0145]). Because the index SNPs were selected for their association with malaria, the results for those SNPs were not adjusted for multiple comparisons. The results for the proxy SNPs were considered exploratory.

3. Results {#s0035}
==========

Consistent with the study design, the eBL cases and controls were comparable with regard to age, sex, residence in the rural or urban villages, and region of enrollment ([Table 1](#t0005){ref-type="table"}). Among subjects with complete data, 167 of 193 (86·5%) of the eBL cases lived in a village near surface water compared to 449 of 624 (72·0%) of the controls (p \< 0·001). Similarly, 130 of 181 (71·8%) eBL cases had mild anemia compared to 144 of 604 (23·8%) controls (p \< 0·001). There were 50 of 199 (25·1%) eBL cases who reported inpatient malaria treatment \> 12 months before enrollment compared to 120 of 619 (19·4%) controls (p = 0·016). The corresponding numbers of participants reporting outpatient malaria treatment \> 13 months before enrollment was 50 of 199 (25·1%) for eBL cases compared to 58 of 619 (9·4%) for controls (p \< 0·001). Paradoxically, malaria infection was detected only in 70 of 199 (35·2%) eBL cases compared to 351 of 622 (56·3%) controls (p \< 0·001).Table 1Demographic and clinical characteristics of the study population.Table 1CharacteristicCases, n (%)Controls, n (%)p valueAll subjects202 (100)624 (100)Age, years (mean ± SD)7·70 (3·28)7·34 (3·40)0·186Age group, years0·568 0--27 (3·5)37 (5·9) 3--552 (25·7)174 (27·8) 6--865 (32·2)197 (31·6) 9--1146 (22·8)134 (21·5) 12--1532 (15·8)82 (13·1)Sex[a](#tf0005){ref-type="table-fn"}0·126 Males122 (61·3)344 (55·1) Females77 (38·7)280 (44·9)Rural/urban[a](#tf0005){ref-type="table-fn"}0·56 Rural118 (61·1)396 (63·5) Urban75 (38·9)228 (36·5)Proximity to surface water[a](#tf0005){ref-type="table-fn"}\< 0·001 Near167 (86·5)449 (72·0) Far26 (13·5)175 (28·0)Study region0·499 Northwest42 (20·8)144 (23·1) North-central160 (79·2)480 (76·9)Anemia[a](#tf0005){ref-type="table-fn"}\< 0·001 Not anemic (Hb \> 11.6 g/dl)51 (28·2)460 (76·2) Anemic (Hb ≤ 11.6 g/dl)130 (71·8)144 (23·8)Inpatient malaria[a](#tf0005){ref-type="table-fn"}0·016 No135 (67·8)413 (66·7) Past 12 months14 (7·0)86 (13·9) \> 13 months50 (25·1)120 (19·4)Outpatient malaria[a](#tf0005){ref-type="table-fn"}\< 0·001 No61 (30·6)141 (22·8) Past 12 months88 (44·2)420 (67·8) \> 13 months50 (25·1)58 (9·4)Malaria infection[a](#tf0005){ref-type="table-fn"}, [b](#tf0010){ref-type="table-fn"}\< 0·001 Negative129 (64·8)271 (43·6) Positive70 (35·2)351 (56·4)[^1][^2]

3.1. Genotype Associations With Burkitt Lymphoma {#s0040}
------------------------------------------------

The genotype associations with eBL for 10 SNPs tested in the total sample set are shown in [Fig. 2](#f0010){ref-type="fig"} and Supplementary Table 4. SCT (*HBB* rs334-AT genotype) was detected in 113 (18·2%) of 620 controls compared to 20 (10·0%) of 200 eBL cases, resulting in a significantly decreased crude OR of eBL risk (OR = 0·50, 95% CI 0·30--0·83). The significantly decreased risk of eBL associated with SCT became more pronounced after controlling for confounders (ORadj = 0·37, 95% CI 0·21--0·66). Carriage of homozygous *HBB* rs334-TT genotype, which corresponds to the sickle cell disease, was seen only in four controls and none of the eBL cases. These children were excluded from the analysis of SCT. In contrast, *HBB* rs160912 was unrelated to eBL.Fig. 2Forest plots showing the associations between selected index or proxy SNPs with eBL risk (a) or with malaria infection in the controls (b). The open circles show crude odds ratios (ORs) and the black squares show ORs adjusted for covariates (see methods). The horizontal lines with vertical bars at the end depict 95% confidence intervals of the ORs. \*Indicates the results that are statistically significant at p ≤ 0·05 (see text and Supplementary tables for details).Fig. 2

We also observed a significantly decreasing trend of eBL risk with carriage of heterozygous or homozygous minor alleles for index SNP *IL10* rs1800896, and proxy SNPs *IL1A* rs2856838 and *SEMA3C* rs4461841 ([Fig. 2](#f0010){ref-type="fig"}). Compared to children with the *IL10* rs1800896-TT genotype, carriage of -CT genotype (ORadj = 0·73, 95% CI 0·50--1·07) and -CC genotype (ORadj = 0·53, 95% CI 0·29--0·95) was associated with a significantly decreasing trend of the adjusted risk of eBL (ptrend = 0·0195). Compared to children with the *IL1A* rs2856838-GG genotype, carriage of -AG genotype (ORadj = 0·56, 95% CI 0·39--0·81) and -AA genotype (ORadj = 0·50, 95% CI 0·25--1·01) was associated with a significantly decreasing trend of the adjusted risk of eBL (ptrend = 0·0016). Compared to children with the *SEMA3C* rs4461841-TT genotype, carriage of the -CC and -CT genotypes were associated with a significantly decreased risk of eBL (ORadj = 0·57, 95% CI 0·35--0·93; pheterogeneity = 0·0193).

The minor allele for *CD36* rs3211938-G was uncommon (4.4%) among the controls. Consistent with the literature that *CD36* rs3211938-G is potentially associated with malaria susceptibility ([@bb0005]) carriage of the -GG/-GT genotypes was associated with an elevated risk of eBL (ORadj = 1·73, 95% CI 1·00--3·00; pheterogeneity = 0·055) compared to carriage of the -TT genotype. Carriage of *IFNAR1* rs914142-AA was associated with a non-significantly elevated risk of eBL (ORadj = 1·32, 95% CI 0·90--1·92; pheterogeneity = 0·152). Carriage of *SEMA3C* rs17154508 and *IFNAR1* rs1041429 were not associated with significant increase or decrease in eBL risk.

The reduced risk of eBL associated with SCT, *IL10* rs1800896, *IL1A* rs2856838, and *SEMA3C* rs4461841 genotypes remained statistically significant in analyses adjusting these genotypes for one another ([Fig. 2](#f0010){ref-type="fig"} and Supplementary Table 4).

3.2. Analysis Stratified by Age {#s0045}
-------------------------------

Stratified analysis of eBL risk was evaluated for in children \< 9 vs. ≥ 9 years ([Table 2](#t0010){ref-type="table"}). The risk of eBL associated with SCT was statistically significant both in younger (ORadj = 0·39, 95% CI 0·18--0·84) and older (ORadj = 0·36, 95% CI 0·15--0·89) children. The adjusted association of eBL risk with *CD36* rs3211938-GG or GT genotypes increased from 1·43 (95% CI 0·68--2·98) in younger children to 2·51 (95% CI 1·05--6·04) in older children, but the ORs were not statistically different from each other (pheterogeneity = 0·197). The association of eBL risk with *IFNAR1* rs914142-AA was significantly elevated in younger children (ORadj = 1·99, 95% CI 1·21--3·28), but not in older children (ORadj = 0·75, 95% CI 0·40--1·39; pheterogeneity = 0·015).Table 2Association between genotypes of index malaria resistance polymorphisms or their proxies with Burkitt Lymphoma, stratified by age group.Table 2GeneSNPGenotype\< 9 years9--15 yearsp-Value for heterogeneityAdjusted OR (95% CI)[c](#tf0025){ref-type="table-fn"}Adjusted OR (95% CI)[c](#tf0025){ref-type="table-fn"}*IL10*rs1800896[a](#tf0015){ref-type="table-fn"}*IL10*[b](#tf0020){ref-type="table-fn"}TTRef.Ref.CT0·87 (0·54--1·41)0·55 (0·29--1·05)CC0·40 (0·18--0·91)0·66 (0·26--1·64)p = 0·064p = 0·191p = 0·445*IL10*rs3024500[a](#tf0015){ref-type="table-fn"}*IL10*AARef.Ref.AG0·93 (0·57--1·51)0·80 (0·40--1·60)GG0·47 (0·23--0·99)0·742 (0·32--1·17)p = 0·096p = 0·756p = 0·465*IL1A*rs2856838*IL1A*GGRef.Ref.AG0·67 (0·42--1·07)0·48 (0·25--0·900)AA0·51 (0·19--1·36)0·60 (0·20--1·82)p = 0·143p = 0·066p = 0·697*CD36*rs3211938[a](#tf0015){ref-type="table-fn"}*CD36*TTRef.Ref.GG/GT1·43 (0·68--2·98)2·51 (1·05--6·041)p = 0·354p = 0·040p = 0·197*SEMA3C*rs17154508*SEMA3C*CT/TTRef.Ref.CC0·89 (0·56--1·42)0·57 (0·31--1·070)p = 0·628p = 0·075p = 0·284*SEMA3C*rs4461841*SEMA3C*TTRef.Ref.CC/CT0·61 (0·33--1·15)0·49 (0·21--1·16)p = 0·115p = 0·092p = 0·567*HBB*rs1609812*HBB*AARef.Ref.AG/GG1·57 (0·90--2·73)1·30 (0·59--2·85)p = 0·116p = 0·514p = 0·587*HBB*rs334[a](#tf0015){ref-type="table-fn"}*HBB*AARef.Ref.AT0·39 (0·18--0·84)0·36 (0·15--0·89)p = 0·010p = 0·019p = 0·930*IFNAR1*rs1041429*IFNAR1*GGRef.Ref.)AG0·92 (0·43--1·49)0·76 (0·40--1·42)AA0·48 (0·22--1·04)0·72 (0·25--2·06)p = 0·141p = 0·640p = 0·477*IFNAR1*rs914142*IFNAR1*AG/GGRef.Ref.AA1·99 (1·21--3·28)0·75 (0·40--1·39)p = 0·007p = 0·356p = 0·015[^3][^4][^5]

3.3. Genotype Associations With Asymptomatic Malaria Infection {#s0050}
--------------------------------------------------------------

The risks of malaria infection associated with the 10 SNPs in the controls are shown in [Fig. 2](#f0010){ref-type="fig"} and Supplementary Table 5. SCT was associated with decreased risk of malaria infection, but in keeping with other studies ([@bb0025]), the effect was modest (ORadj = 0·74 (0·48--1·14). Carriage of heterozygous or homozygous minor alleles of index SNPs *IL10* rs1800896 and *IL10* rs3024500, and proxy SNPs *IL1A* rs2856838 and *IFNAR1* rs1041429 was associated with decreased risk of malaria (all p \< 0·05). Proxy SNP *SEMA3C* rs4461841, which was associated with significantly decreased risk of eBL, was not associated with malaria (Supplementary Table 5).

4. Discussion {#s0055}
=============

We found that SCT was associated with a two-fold lower risk of eBL using Mendelian Randomization in a population-based study in northern Uganda, where we previously demonstrated high malaria prevalence ([@bb0130]). We observed a similar effect of SCT on eBL in younger and older children, suggesting that the effect of SCT on eBL is similar regardless of whether a child relies more on adaptive or innate malaria immune responses. Our results confirm those reported by Williams in Nigeria ([@bb0225]), by Pike and colleagues in Uganda ([@bb0175]), and by Hesseling and colleagues in Cameroon ([@bb0090]), albeit from smaller studies that were under powered. Our results strengthen the evidence of a causal link between malaria and eBL that was previously suggested by observational epidemiology ([@bb0030]).

We also found that the index SNP *IL10* rs1800896 was significantly inversely associated with malaria infection among controls, consistent with reports that it is protective against malaria infection in the Brazilian Amazon ([@bb0050]), Cameroon ([@bb0015]), Southwest Benin ([@bb0120]), Malawi, Kenya, Ghana, and Tanzania ([@bb0110]), and that it was associated with significantly decreased risk of eBL. The inverse associations with both malaria and eBL suggest the effect of *IL10* rs1800896 on eBL may be mediated by protection against malaria, and suggest that *IL10* rs1800896 is an additional polymorphism to SCT that influences eBL risk by modulating malaria risk. SCT and *IL10* rs1800896 may influence the risk of eBL by decreasing the frequency of malaria, the peak malaria parasite density, the duration of parasitemia, or the degree of inflammation per infection. We hypothesize that the effects of these polymorphisms lead to decreased cumulative load of malaria antigens reaching the germinal center B cells ([@bb0185]), attenuation of effects of malaria infections on Epstein-Barr infection ([@bb0190]), and, plausibly, a proportionate decrease in the stimulation of germinal center B cells and decrease in the risk of developing DNA modifications necessary for initiating eBL.

Our finding of significant inverse associations between eBL risk and proxy SNPs *IL1A* rs2856838 and *SEMA3C* rs4461841 are novel, and warrant further exploration. SNP rs2856838 is located within an intron of *IL1A* and has no known functional significance or association with mRNA expression in human tissues ([@bb0045]). It was selected as a proxy (r2 = 0·085; D′ = 1·00) for index SNP *IL1A* rs17561 (Ala114Ser), which is associated with malaria infection ([@bb0220]), but was not associated with eBL risk at the priortization stage (Supplementary Fig. 2), while its proxy rs2856838 was associated with eBL risk and with malaria in the controls ([Fig. 2](#f0010){ref-type="fig"}). Similarly, *SEMA3C* rs4461841 was selected as a proxy (r2 = 0·006 and D′ = 1·00) for index SNP *CD36* rs3211938 (Tyr325STOP), which is under positive selection in endemic malaria populations, including the Yoruba ([@bb0005]). CD36 mediates cytoadherence of the *Pf* erythrocyte membrane protein 1 (*Pf*EMP1) virulence protein ([@bb0155]) which mediates the sequestration of infected erythrocytes in peripheral tissues and impairs the clearance of parasites by stopping filtration of parasites through the spleen ([@bb0205]). The strong D′ (1.00) but low r2 (0.006) between the SNPs suggests that they are residing on the same haplotype. Both *SEMA3C* rs4461841 and *CD36* rs3211938 were associated with eBL risk, but the association was stronger with rs4461841 than with rs3211938.

Our questionnaire data support the hypothesis that eBL cases are more likely to be exposed to heavy malaria than controls, based on being more likely to live in a village near surface water, to report inpatient or outpatient malaria history \> 13 months before enrollment, and to have mild anemia. The results also illustrate the difficulties of using observational epidemiological methods to measure complex exposures, such as malaria. For example, using blood tests for malaria and questionnaire data, we found that eBL cases were less likely to test positive for malaria and less likely to report inpatient or outpatient malaria history \< 13 months before enrollment, which are paradoxical given the associations noted above suggesting greater likelihood of the eBL cases to be exposed to heavy malaria. Similar paradoxical findings of malaria parasitemia have been reported in Kenya ([@bb0020]) and in a prospective study in Uganda ([@bb0055]), but they were dismissed based on casual reports and assumptions that eBL cases were more likely to have been treated with anti-malarial drugs prior to admission than controls. We excluded this explanation using our more detailed data. For example, the results from thick film microscopy (TFM), which measures current malaria, were similar to those from rapid diagnostic tests (RDT), which remain positive for 3--4 weeks after treatment of symptomatic malaria ([@bb0075]), and the questionnaire data on inpatient and outpatient malaria history 12 months before enrollment suggested lower malaria morbidity in the eBL cases than the controls. These paradoxical results may be a clue to the nature of malaria immunity in eBL cases that increases their tolerance for acute malaria morbidity ([@bb0060]), while exposing them to heightened risk of other, later-onset, malaria complications, such as eBL. This paradox may be examined by invoking the Greek myth of Charybdis and Scylla, where children exposed to heavy malaria are evolutionarily adapted to reduce their risks of complications of acute clinical malaria infections, which are associated with higher mortality. This tolerant state to malaria may manifest as a lower frequency of malaria parasitemia and of inpatient and outpatient malaria symptoms, but with a long-term increase in the risk of eBL due to chronic antigenic stimulation ([@bb0185]), probably by low level genetically diverse malaria strains ([@bb0100]).

The strengths of our study include the use of well-matched cases and controls selected from a geographically defined population-based study area with known malaria prevalence ([@bb0130]), detailed covariate data about malaria exposures, data to assess the impact of population genetic structure, and using multiple genotyping methods to assess polymorphisms. The associations with proxy SNPs may represent false-positive findings or novel findings that should be explored further. Our results encourage a more complete assessment of the effect of malaria on eBL using Mendelian Randomization analysis. For example the effects on eBL of genes whose protection against malaria has been reported in recent studies, such as blood group O ([@bb0070]), *G6PD* ([@bb0040]), *FREM3/GYPE* ([@bb0125]), *EPB41*, *GYPB* ([@bb0115]), and *ATP2B4* and *MARVELD3* ([@bb0215]) were not assessed in the current study because they were not covered by the Infinium Omni5Exome-4 v1.3 BeadChip used to prioritize SNPs.

In summary, we found, consistent with the literature, that SCT and *IL10* rs1800896 were associated with decreased risk of asymptomatic malaria in the controls and associated with decreased risk of eBL using Mendelian Randomization analysis. We found inverse associations between *IL1A* SNPs rs2856838 and *SEMA3C* rs4461841 with eBL, which require further study. Our findings of inverse associations between SCT and *IL10* rs1800896 using Mendelian Randomization support a causal effect of malaria on eBL. These results support the idea of strengthening of public health messages to stress eBL as a complication of malaria infection.
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[^1]: Computation of percentages did not include categories with missing information. Three subjects with discordant gender on different forms were coded as missing for gender.

[^2]: Malaria infection status was determined by thick film microscopy or rapid diagnostic test results as described in [@bb0130]. As \< 2·1% of the controls had a current fever, malaria infection was considered incidental in asymptomatic subjects.

[^3]: Index SNP, otherwise proxy SNP.

[^4]: SNP genotypes were coded using an additive genetic model that counts the number of minor alleles. Genotypes for uncommon alleles were coded by combining the minor homozygotes and heterozygotes in one group.

[^5]: Adjusted for gender, age group, current malaria infection (see text in methods), region, inpatient and outpatient malaria treatment (base model). Individuals with missing data for the exposure variable of interest were excluded from the model when estimating the association.
